<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (sAML) may arise from the previous clonal disorder of hematopoiesis, usually from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or from <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloproliferative <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (cMPN) or after exposure to a leukemogenic agent (previous chemotherapy or radiotherapy, some immunosuppressive drugs or environmental leukemogenic agents) </plain></SENT>
<SENT sid="1" pm="."><plain>Secondary origin of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is associated with unfavorable prognosis and it is not considered to be conventionally curable (with the exception of secondary <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>The presented study is a retrospective analysis of patients diagnosed and treated at the Department of Hemato-<z:hpo ids='HP_0002664'>Oncology</z:hpo>, University Hospital Olomouc in 1996-2008 </plain></SENT>
<SENT sid="3" pm="."><plain>Over that period of time, a total 574 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were diagnosed </plain></SENT>
<SENT sid="4" pm="."><plain>Of those, 430 patients were diagnosed as having primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; in 86 patients, sAML transformed from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and 58 patients were followed or treated for various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> or were treated with potentially leukemogenic agents because of non-malignant disorders </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> are older and less commonly treated with curative intention than those with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>According to cytogenetic findings, their prognosis is often worse </plain></SENT>
<SENT sid="7" pm="."><plain>Complete hematologic remission is achieved with a low probability, relapse of the disease occurs frequently and overall survival is worse in almost <z:hpo ids='HP_0000001'>all</z:hpo> prognostic subgroups </plain></SENT>
<SENT sid="8" pm="."><plain>With the exception of secondary <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo>, the prognosis of which does not differ from very good prognosis of the primary forms, <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> is not considered a conventionally curable disease </plain></SENT>
</text></document>